{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:46:47Z","timestamp":1792090007039,"version":"4.4.0"},"reference-count":154,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2014,5,8]],"date-time":"2014-05-08T00:00:00Z","timestamp":1399507200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s40620-014-0103-y","type":"journal-article","created":{"date-parts":[[2014,5,7]],"date-time":"2014-05-07T08:27:43Z","timestamp":1399451263000},"page":"495-506","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["mTOR inhibitors and renal allograft: Yin and Yang"],"prefix":"10.1093","volume":"27","author":[{"given":"Gianluigi","family":"Zaza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Granata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Tomei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Masola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Gambaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Lupo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,5,8]]},"reference":[{"key":"103_CR1","unstructured":"Cecka JM The UNOS renal transplant registry. Clin Transpl 2005:1\u201316"},{"key":"103_CR2","first-page":"486","volume":"153","author":"TE Starzl","year":"1981","unstructured":"Starzl TE, Klintmalm GB, Weil R III et al (1981) Cyclosporin A and steroid therapy in sixty-six cadaver kidney recipients. Surg Gynecol Obstet 153:486\u2013494","journal-title":"Surg Gynecol Obstet"},{"issue":"4 Pt 2","key":"103_CR3","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1600-6143.2010.03021.x","volume":"10","author":"RA Wolfe","year":"2010","unstructured":"Wolfe RA, Roys EC, Merion RM (2010) Trends in organ donation and transplantation in the United States, 1999-2008. Am J Transplant 10(4 Pt 2):961\u2013972","journal-title":"Am J Transplant"},{"key":"103_CR4","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1111\/j.1600-6143.2008.02391.x","volume":"8","author":"EK Geissler","year":"2008","unstructured":"Geissler EK, Schlitt HJ, Thomas G (2008) mTOR, cancer, and transplantation. Am J Transplant 8:2212\u20132218","journal-title":"Am J Transplant"},{"key":"103_CR5","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1016\/j.transproceed.2007.09.008","volume":"39","author":"JR Chapman","year":"2007","unstructured":"Chapman JR, Valantine H, Albanell J et al (2007) Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy. Transplant Proc 39:2937\u20132950","journal-title":"Transplant Proc"},{"key":"103_CR6","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0009-9120(98)00045-9","volume":"31","author":"SN Sehgal","year":"1998","unstructured":"Sehgal SN (1998) Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunnuosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 31:335\u2013340","journal-title":"Clin Biochem"},{"issue":"9225","key":"103_CR7","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0140-6736(00)02480-6","volume":"356","author":"BD Kahan","year":"2000","unstructured":"Kahan BD, For the Rapamune US Study Group (2000) Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomized multicentre study. Lancet 356(9225):194\u2013202","journal-title":"Lancet"},{"issue":"2","key":"103_CR8","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00007890-200101270-00019","volume":"71","author":"AS MacDonald","year":"2001","unstructured":"MacDonald AS, For the Rapamune Global Study Group (2001) A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus\/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 71(2):271\u2013280","journal-title":"Transplantation"},{"issue":"7","key":"103_CR9","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/00007890-199904150-00017","volume":"67","author":"CG Groth","year":"1999","unstructured":"Groth CG, Backman L, Morales JM et al (1999) Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 67(7):1036\u20131042","journal-title":"Transplantation"},{"issue":"7","key":"103_CR10","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1097\/00007890-200004150-00009","volume":"69","author":"H Kreis","year":"2000","unstructured":"Kreis H, Cisterne JM, Land W et al (2000) Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. The Sirolimus European Renal Transplant Study Group. Transplantation 69(7):1252\u20131260","journal-title":"Transplantation"},{"issue":"8","key":"103_CR11","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1111\/j.1600-6143.2011.03573.x","volume":"11","author":"SM Flechner","year":"2011","unstructured":"Flechner SM, Glyda M, Cockfield S et al (2011) The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant 11(8):1633\u20131644","journal-title":"Am J Transplant"},{"issue":"2","key":"103_CR12","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/01.TP.0000164352.65613.24","volume":"80","author":"MI Lorber","year":"2005","unstructured":"Lorber MI, Mulgaonkar S, Butt KM (2005) Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 80(2):244\u2013252","journal-title":"Transplantation"},{"key":"103_CR13","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","volume":"375","author":"H Ekberg","year":"2007","unstructured":"Ekberg H, Tedesco-Silva H, Demirbas A et al (2007) Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 375:2562\u20132575","journal-title":"N Engl J Med"},{"issue":"10","key":"103_CR14","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1111\/j.1600-6143.2005.01063.x","volume":"5","author":"S Vitko","year":"2005","unstructured":"Vitko S, Margreiter R, Weimar W et al (2005) Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 5(10):2521\u20132530","journal-title":"Am J Transplant"},{"key":"103_CR15","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/01.TP.0000101495.22734.07","volume":"77","author":"G Ciancio","year":"2004","unstructured":"Ciancio G, Burke GW, Gaynor JJ et al (2004) A randomized long-term trial of tacrolimus\/sirolimus versus tacrolimus\/mycophenolate mofetil versus cyclosporine (NEORAL)\/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1\u00a0year. Transplantation 77:252\u2013258","journal-title":"Transplantation"},{"key":"103_CR16","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1600-6143.2005.01177.x","volume":"6","author":"TS Larson","year":"2006","unstructured":"Larson TS, Dean PG, Stegall MD et al (2006) Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 6:514\u2013522","journal-title":"Am J Transplant"},{"issue":"3","key":"103_CR17","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/01.tp.0000167757.63922.42","volume":"80","author":"R Mendez","year":"2005","unstructured":"Mendez R, Gonwa T, Yang HC, Weinstein S, Jensik S, Steinberg S, Prograf Study Group (2005) A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1\u00a0year. Transplantation 80(3):303\u2013309","journal-title":"Transplantation"},{"issue":"6","key":"103_CR18","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1097\/01.tp.0000173378.28790.0b","volume":"80","author":"MS Anil Kumar","year":"2005","unstructured":"Anil Kumar MS, Heifets M, Fyfe B, Saaed MI, Moritz MJ, Parikh MH, Kumar A (2005) Comparison of steroid avoidance in tacrolimus\/mycophenolate mofetil and tacrolimus\/sirolimus combination in kidney transplantation monitored by surveillance biopsy. Transplantation 80(6):807\u2013814","journal-title":"Transplantation"},{"issue":"7","key":"103_CR19","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1111\/j.1600-6143.2006.01340.x","volume":"6","author":"L Gallon","year":"2006","unstructured":"Gallon L, Perico N, Dimitrov BD, Winoto J, Remuzzi G, Leventhal J, Gaspari F, Kaufman D (2006) Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs. MMF. Am J Transplant 6(7):1617\u20131623","journal-title":"Am J Transplant"},{"key":"103_CR20","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1097\/00007890-200210270-00002","volume":"74","author":"SM Flechner","year":"2002","unstructured":"Flechner SM, Goldfarb D, Modlin C, Feng J, Krishnamurthi V, Mastroianni B, Savas K, Cook DJ, Novick AC (2002) Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 74:1070\u20131076","journal-title":"Transplantation"},{"key":"103_CR21","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/j.1600-6143.2005.01055.x","volume":"5","author":"CJ Watson","year":"2005","unstructured":"Watson CJ, Firth J, Williams PF et al (2005) A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant 5:2496\u20132503","journal-title":"Am J Transplant"},{"key":"103_CR22","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1681\/ASN.2005060635","volume":"16","author":"G Stallone","year":"2005","unstructured":"Stallone G, Infante B, Schena A et al (2005) Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 16:3755\u20133762","journal-title":"J Am Soc Nephrol"},{"key":"103_CR23","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/TP.0b013e3181927a41","volume":"87","author":"FP Schena","year":"2009","unstructured":"Schena FP, Pascoe MD, Alberu J et al (2009) Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 87:233\u2013242","journal-title":"Transplantation"},{"key":"103_CR24","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/j.1600-6143.2009.02615.x","volume":"9","author":"Y Lebranchu","year":"2009","unstructured":"Lebranchu Y, Thierry A, Toupance O et al (2009) Efficacy on renal function of early conversion from cyclosporine to sirolimus 3\u00a0months after renal transplantation: concept study. Am J Transplant 9:1115\u20131123","journal-title":"Am J Transplant"},{"key":"103_CR25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/dat.20530","volume":"40","author":"SJ Patel","year":"2011","unstructured":"Patel SJ, Dawson KL, Knight RJ et al (2011) The role of mTOR inhibition in renal transplant immune suppression. Dial Transplant 40:23\u201329","journal-title":"Dial Transplant"},{"key":"103_CR26","unstructured":"Penn I (1998) Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl 147\u2013158"},{"issue":"6","key":"103_CR27","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1600-6143.2004.00450.x","volume":"4","author":"BL Kasiske","year":"2004","unstructured":"Kasiske BL, Snyder JJ, Gilbertson DT, Wang C (2004) Cancer after kidney transplantation in the United States. Am J Transplant 4(6):905\u2013913","journal-title":"Am J Transplant"},{"issue":"6","key":"103_CR28","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/MNH.0b013e3282f06bba","volume":"16","author":"B Vasudev","year":"2007","unstructured":"Vasudev B, Hariharan S (2007) Cancer after renal transplantation. Curr Opin Nephrol Hypertens 16(6):523\u2013528","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"2 Suppl","key":"103_CR29","doi-asserted-by":"crossref","first-page":"S254","DOI":"10.1097\/01.tp.0000186382.81130.ba","volume":"80","author":"JF Buell","year":"2005","unstructured":"Buell JF, Gross TG, Woodle ES (2005) Malignancy after transplantation. Transplantation 80(2 Suppl):S254\u2013S264","journal-title":"Transplantation"},{"issue":"Suppl 1","key":"103_CR30","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/ndt\/gfm085","volume":"22","author":"J Dantal","year":"2007","unstructured":"Dantal J, Pohanka E (2007) Malignancies in renal transplantation: an unmet medical need. Nephrol Dial Transplant 22(Suppl 1):i4\u2013i10","journal-title":"Nephrol Dial Transplant"},{"issue":"23","key":"103_CR31","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1001\/jama.296.23.2823","volume":"296","author":"CM Vajdic","year":"2006","unstructured":"Vajdic CM, MacDonald SP, McCredie MR et al (2006) Cancer incidence before and after kidney transplantation. JAMA 296(23):2823\u20132831","journal-title":"JAMA"},{"issue":"4","key":"103_CR32","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1600-6143.2007.01736.x","volume":"7","author":"PJ Villeneuve","year":"2007","unstructured":"Villeneuve PJ, Schaubel DE, Fenton SS, Shepherd FA, Jiang Y, Mao Y (2007) Cancer incidence among Canadian kidney transplant recipients. Am J Transplant 7(4):941\u2013948","journal-title":"Am J Transplant"},{"key":"103_CR33","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1097\/00007890-200205270-00008","volume":"73","author":"FL Luan","year":"2002","unstructured":"Luan FL, Hojo M, Maluccio M, Yamaji K, Suthanthiran M (2002) Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 73:1565\u20131572","journal-title":"Transplantation"},{"issue":"2","key":"103_CR34","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm0202-128","volume":"8","author":"M Guba","year":"2002","unstructured":"Guba M, von Breitenbuch P, Steinbauer M et al (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8(2):128\u2013135","journal-title":"Nat Med"},{"key":"103_CR35","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/01.TP.0000184006.43152.8D","volume":"80","author":"HM Kauffman","year":"2005","unstructured":"Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD (2005) Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 80:883\u2013889","journal-title":"Transplantation"},{"key":"103_CR36","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1399-0012.2004.00188.x","volume":"18","author":"T Mathew","year":"2004","unstructured":"Mathew T, Kreis H, Friend P (2004) Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 18:446\u2013449","journal-title":"Clin Transplant"},{"key":"103_CR37","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1681\/ASN.2005090993","volume":"17","author":"JM Campistol","year":"2006","unstructured":"Campistol JM, Eris J, Oberbauer R et al (2006) Sirolimus therapy after early cyclosporine withdrawal reduces the risk of cancer in adult renal transplantation. J Am Soc Nephrol 17:581\u2013589","journal-title":"J Am Soc Nephrol"},{"key":"103_CR38","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/01.TP.0000115344.18025.0B","volume":"77","author":"JM Campistol","year":"2004","unstructured":"Campistol JM, Gutierrez-Dalmau A, Torregrosa JV (2004) Conversion to sirolimus: a successful treatment for posttransplantation Kaposi\u2019s sarcoma. Transplantation 77:760\u2013762","journal-title":"Transplantation"},{"key":"103_CR39","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1111\/j.1600-6143.2006.01412.x","volume":"6","author":"C Lebbe","year":"2006","unstructured":"Lebbe C, Euvrard S, Barrou B et al (2006) Sirolimus conversion for patients with posttransplant Kaposi\u2019s sarcoma. Am J Transplant 6:2164\u20132168","journal-title":"Am J Transplant"},{"issue":"2","key":"103_CR40","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.transproceed.2004.12.172","volume":"37","author":"SC Zmonarski","year":"2005","unstructured":"Zmonarski SC, Boraty\u0144ska M, Rabczy\u0144ski J, Kazimierczak K, Klinger M (2005) Regression of Kaposi\u2019s sarcoma in renal graft recipients after conversion to sirolimus treatment. Transplant Proc 37(2):964\u2013966","journal-title":"Transplant Proc"},{"issue":"13","key":"103_CR41","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa042831","volume":"352","author":"G Stallone","year":"2005","unstructured":"Stallone G, Schena A, Infante B et al (2005) Sirolimus for Kaposi\u2019s sarcoma in renal transplant patients. N Engl J Med 352(13):1317\u20131323","journal-title":"N Engl J Med"},{"issue":"8","key":"103_CR42","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1093\/ndt\/gfh884","volume":"20","author":"JS Zaltzman","year":"2005","unstructured":"Zaltzman JS, Prasad R, Chun K, Jothy S (2005) Resolution of renal allograft associated post-transplant lymphoproliferative disorder with introduction of sirolimus. Nephrol Dial Transplant 20(8):1748\u20131751","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"103_CR43","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.transproceed.2007.03.092","volume":"39","author":"N Mohsin","year":"2007","unstructured":"Mohsin N, Budrudden M, Kamble P et al (2007) Complete regression of cutaneous B cell lymphoma in a renal transplant patient after conversion from cyclosporine to sirolimus. Transplant Proc 39(4):1267\u20131271","journal-title":"Transplant Proc"},{"issue":"5","key":"103_CR44","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1053\/j.ajkd.2006.01.029","volume":"47","author":"B Cullis","year":"2006","unstructured":"Cullis B, D\u2019Souza R, McCullagh P et al (2006) Sirolimus\u2014induced remission of posttransplantation lymphoproliferative disorder. Am J Kidney Dis 47(5):e67\u2013e72","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"103_CR45","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1399-3046.2004.00156.x","volume":"8","author":"C Jim\u00e9nez-Rivera","year":"2004","unstructured":"Jim\u00e9nez-Rivera C, Avitzur Y, Fecteau AH, Jones N, Grant D, Ng VL (2004) Sirolimus for pediatric liver transplant recipients with posttransplant lymphoproliferative disease and hepatoblastoma. Pediatr Transplant 8(3):243\u2013248","journal-title":"Pediatr Transplant"},{"issue":"3","key":"103_CR46","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1432-2277.2003.tb00287.x","volume":"16","author":"VD Garcia","year":"2003","unstructured":"Garcia VD, Bonamigo Filho JL, Neuman J et al (2003) Rituximab in association with rapamycin for posttransplant lymphoproliferative disease treatment. Transpl Int 16(3):202\u2013206","journal-title":"Transpl Int"},{"issue":"2","key":"103_CR47","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1399-3046.2005.00253.x","volume":"9","author":"SI Al-Akash","year":"2005","unstructured":"Al-Akash SI, Al Makadma AS, Al Omari MG (2005) Rapid response to rituximab in a pediatric liver transplant recipient with posttransplant lymphoproliferative disease and maintenance with sirolimus monotherapy. Pediatr Transplant 9(2):249\u2013253","journal-title":"Pediatr Transplant"},{"key":"103_CR48","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1046\/j.1523-1755.62.s82.16.x","volume":"82","author":"JM Morales","year":"2002","unstructured":"Morales JM (2002) Influence of the new immunosuppressive combinations on arterial hypertension after renal transplantation. Kidney Int Suppl 82:S81\u2013S87","journal-title":"Kidney Int Suppl"},{"issue":"3 Suppl","key":"103_CR49","doi-asserted-by":"crossref","first-page":"151S","DOI":"10.1016\/S0041-1345(03)00241-0","volume":"35","author":"C Legendre","year":"2003","unstructured":"Legendre C, Campistol JM, Squifflet JP et al (2003) Sirolimus European Renal Transplant Study Group: cardiovascular risk factors of sirolimus compared with cyclosporine: early experience from two randomized trials in renal transplantation. Transplant Proc 35(3 Suppl):151S\u2013153S","journal-title":"Transplant Proc"},{"key":"103_CR50","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/TP.0b013e318242be28","volume":"93","author":"E Paoletti","year":"2012","unstructured":"Paoletti E, Marsano L, Bellino D, Cassottana P, Cannella G (2012) Effect of everolimus on left ventricular hypertrophy of de novo kidney transplant recipients: a 1\u00a0year, randomized, controlled trial. Transplantation 93:503\u2013508","journal-title":"Transplantation"},{"issue":"11","key":"103_CR51","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1111\/j.1600-6143.2011.03697.x","volume":"11","author":"R Joannid\u00e8s","year":"2011","unstructured":"Joannid\u00e8s R, Monteil C, de Ligny BH et al (2011) Immunosuppressant regimen based on sirolimus decreases aortic stiffness in renal transplant recipients in comparison to cyclosporine. Am J Transplant 11(11):2414\u20132422","journal-title":"Am J Transplant"},{"key":"103_CR52","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1097\/00007890-199805150-00023","volume":"65","author":"C Brattstrom","year":"1998","unstructured":"Brattstrom C, Wilczek H, Tyden G et al (1998) Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation 65:1272\u20131274","journal-title":"Transplantation"},{"issue":"6","key":"103_CR53","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1093\/ndt\/gfp778","volume":"25","author":"H Ekberg","year":"2010","unstructured":"Ekberg H, Bernasconi C, N\u00f6ldeke J et al (2010) Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. Nephrol Dial Transplant 25(6):2004\u20132010","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"103_CR54","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1399-3062.2010.00526.x","volume":"12","author":"J Fortun","year":"2010","unstructured":"Fortun J, Martin-Davila P, Pascual J et al (2010) Immunosuppressive therapy and infection after kidney transplantation. Transpl Infect Dis 12(5):397\u2013405","journal-title":"Transpl Infect Dis"},{"issue":"3","key":"103_CR55","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/ki.2008.580","volume":"75","author":"JJ Snyder","year":"2009","unstructured":"Snyder JJ, Israni AK, Peng Y et al (2009) Rates of first infection following kidney transplant in the United States. Kidney Int 75(3):317\u2013326","journal-title":"Kidney Int"},{"issue":"11","key":"103_CR56","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/TP.0b013e31824810e6","volume":"93","author":"B Nashan","year":"2012","unstructured":"Nashan B, Gaston R, Emery V et al (2012) Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation 93(11):1075\u20131085","journal-title":"Transplantation"},{"key":"103_CR57","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature08155","volume":"460","author":"K Araki","year":"2009","unstructured":"Araki K, Turner AP, Shaffer VO et al (2009) mTOR regulates memory CD8 T-cell differentiation. Nature 460:108\u2013112","journal-title":"Nature"},{"key":"103_CR58","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/01.tp.0000268524.27506.39","volume":"84","author":"CA Benavides","year":"2007","unstructured":"Benavides CA, Pollard VB, Mauiyyedi S, Podder H, Knight R, Kahan BD (2007) BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes. Transplantation 84:83\u201388","journal-title":"Transplantation"},{"key":"103_CR59","doi-asserted-by":"crossref","first-page":"403280","DOI":"10.1155\/2013\/403280","volume":"2013","author":"G Zaza","year":"2013","unstructured":"Zaza G, Tomei P, Ria P, Granata S, Boschiero L, Lupo A (2013) Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors. Clin Dev Immunol 2013:403280","journal-title":"Clin Dev Immunol"},{"issue":"8","key":"103_CR60","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1016\/j.transproceed.2010.07.083","volume":"42","author":"AI S\u00e1nchez-Fructuoso","year":"2010","unstructured":"S\u00e1nchez-Fructuoso AI, Ruiz JC, P\u00e9rez-Flores I et al (2010) Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus. Transplant Proc 42(8):3050\u20133052","journal-title":"Transplant Proc"},{"issue":"1","key":"103_CR61","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.trre.2011.10.003","volume":"26","author":"F Diekmann","year":"2012","unstructured":"Diekmann F, Andres A, Oppenheimer F (2012) mTOR inhibitor-associated proteinuria in kidney transplant recipients. Transplant Rev (Orlando) 26(1):27\u201329","journal-title":"Transplant Rev (Orlando)"},{"key":"103_CR62","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1111\/j.1600-6143.2004.00590.x","volume":"4","author":"F Diekmann","year":"2004","unstructured":"Diekmann F, Budde K, Oppenheimer F, Fritsche L, Neumayer HH, Campistol JM (2004) Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 4:1869\u20131875","journal-title":"Am J Transplant"},{"issue":"9","key":"103_CR63","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1097\/01.tp.0000185200.17589.74","volume":"80","author":"E Letavernier","year":"2005","unstructured":"Letavernier E, Pe\u2019raldi MN, Pariente A, Morelon E, Legendre C (2005) Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 80(9):1198\u20131203","journal-title":"Transplantation"},{"issue":"3 Suppl","key":"103_CR64","doi-asserted-by":"crossref","first-page":"52S","DOI":"10.1016\/S0041-1345(03)00244-6","volume":"35","author":"E Morelon","year":"2003","unstructured":"Morelon E, Kreis H (2003) Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience. Transplant Proc 35(3 Suppl):52S\u201357S","journal-title":"Transplant Proc"},{"issue":"9","key":"103_CR65","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nm.1857","volume":"14","author":"C Faul","year":"2008","unstructured":"Faul C, Donnelly M, Merscher-Gomez S et al (2008) The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 14(9):931\u2013938","journal-title":"Nat Med"},{"issue":"2","key":"103_CR66","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/ndt\/gfi266","volume":"21","author":"A Saurina","year":"2006","unstructured":"Saurina A, Campistol JM, Piera C et al (2006) Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria. Nephrol Dial Transplant 21(2):488\u2013493","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"103_CR67","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1111\/j.1523-1755.2005.00732.x","volume":"68","author":"JD Coombes","year":"2005","unstructured":"Coombes JD, Mreich E, Liddle C, Rangan GK (2005) Rapamycin worsens renal function and intratubular cast formation in protein overload nephropathy. Kidney Int 68(6):2599\u20132607","journal-title":"Kidney Int"},{"issue":"6","key":"103_CR68","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1172\/JCI44771","volume":"121","author":"K Inoki","year":"2011","unstructured":"Inoki K, Mori H, Wang J et al (2011) mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest 121(6):2181\u20132196","journal-title":"J Clin Invest"},{"issue":"6","key":"103_CR69","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1172\/JCI44774","volume":"121","author":"M Godel","year":"2011","unstructured":"Godel M, Hartleben B, Herbach N (2011) Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest 121(6):2197\u20132209","journal-title":"J Clin Invest"},{"issue":"12","key":"103_CR70","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1097\/01.TP.0000069831.76067.22","volume":"75","author":"T Gonwa","year":"2003","unstructured":"Gonwa T, Johnson C, Ahsan N (2003) Randomized trial of tacrolimus\u00a0+\u00a0mycophenolate mofetil or azathioprine versus cyclosporine\u00a0+\u00a0mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation 75(12):2048\u20132053","journal-title":"Transplantation"},{"issue":"2","key":"103_CR71","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00007691-199804000-00001","volume":"20","author":"KL Napoli","year":"1998","unstructured":"Napoli KL, Wang ME, Stepkowski SM, Kahan BD (1998) Relative tissue distributions of cyclosporine and sirolimus after concomitant peroral administration to the rat: evidence for pharmacokinetic interactions. Ther Drug Monit 20(2):123\u2013133","journal-title":"Ther Drug Monit"},{"issue":"5","key":"103_CR72","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1681\/ASN.V1251059","volume":"12","author":"H Podder","year":"2001","unstructured":"Podder H, Stepkowski SM, Napoli KL (2001) Pharmacokinetic interactions augment toxicities of sirolimus\/cyclosporine combinations. J Am Soc Nephrol 12(5):1059\u20131071","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"103_CR73","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/sj.ki.5001649","volume":"70","author":"D Anglicheau","year":"2006","unstructured":"Anglicheau D, Pallet N, Rabant M (2006) Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction. Kidney Int 70(6):1019\u20131025","journal-title":"Kidney Int"},{"key":"103_CR74","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1399-0012.2004.00116.x","volume":"18","author":"A Lo","year":"2004","unstructured":"Lo A, Egidi MF, Gaber LW et al (2004) Observations regarding the use of sirolimus and tacrolimus in high-risk cadaveric renal transplantation. Clin Transplant 18:53\u201361","journal-title":"Clin Transplant"},{"key":"103_CR75","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/TP.0b013e318187bab0","volume":"86","author":"AO Gaber","year":"2008","unstructured":"Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF (2008) Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial. Transplantation 86:1187\u20131195","journal-title":"Transplantation"},{"issue":"9","key":"103_CR76","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1097\/00007890-200105150-00025","volume":"71","author":"JC Hong","year":"2001","unstructured":"Hong JC, Kahan BD (2001) A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients at risk for delayed graft function. Transplantation 71(9):1320\u20131328","journal-title":"Transplantation"},{"issue":"4","key":"103_CR77","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1034\/j.1600-6143.2003.00078.x","volume":"3","author":"RA McTaggart","year":"2003","unstructured":"McTaggart RA, Gottlieb D, Brooks J et al (2003) Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transplant 3(4):416\u2013423","journal-title":"Am J Transplant"},{"issue":"4","key":"103_CR78","doi-asserted-by":"crossref","first-page":"F693","DOI":"10.1152\/ajprenal.2001.281.4.F693","volume":"281","author":"W Lieberthal","year":"2001","unstructured":"Lieberthal W, Fuhro R, Andry CC et al (2001) Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 281(4):F693\u2013F706","journal-title":"Am J Physiol Renal Physiol"},{"issue":"11","key":"103_CR79","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/j.1432-2277.2010.01094.x","volume":"23","author":"J Dantal","year":"2010","unstructured":"Dantal J, Berthoux F, Moal MC et al (2010) Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. Transpl Int 23(11):1084\u20131093","journal-title":"Transpl Int"},{"issue":"13","key":"103_CR80","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1056\/NEJMra052131","volume":"354","author":"K Tryggvason","year":"2006","unstructured":"Tryggvason K, Patrakka J, Wartiovaara J (2006) Hereditary proteinuria syndromes and mechanisms of proteinuria. N Engl J Med 354(13):1387\u20131401","journal-title":"N Engl J Med"},{"key":"103_CR81","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1146\/annurev.pathol.1.110304.100119","volume":"1","author":"C Kwoh","year":"2006","unstructured":"Kwoh C, Shannon MB, Miner JH, Shaw A (2006) Pathogenesis of nonimmune glomerulopathies. Annu Rev Pathol 1:349\u2013374","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"103_CR82","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1152\/physrev.00020.2002","volume":"83","author":"H Pavenstadt","year":"2003","unstructured":"Pavenstadt H, Kriz W, Kretzler M (2003) Cell biology of the glomerular podocyte. Physiol Rev 83(1):253\u2013307","journal-title":"Physiol Rev"},{"issue":"12","key":"103_CR83","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1097\/01.ASN.0000039661.06947.FD","volume":"13","author":"P Mundel","year":"2002","unstructured":"Mundel P, Shankland SJ (2002) Podocyte biology and response to injury. J Am Soc Nephrol 13(12):3005\u20133015","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"103_CR84","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1172\/JCI200114629","volume":"108","author":"D Kerjaschki","year":"2001","unstructured":"Kerjaschki D (2001) Caught flat-footed: podocyte damage and the molecular bases of focal glomerulosclerosis. J Clin Invest 108(11):1583\u20131587","journal-title":"J Clin Invest"},{"issue":"6","key":"103_CR85","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1097\/01.ASN.0000130167.30769.55","volume":"15","author":"T Benzing","year":"2004","unstructured":"Benzing T (2004) Signaling at the slit diaphragm. J Am Soc Nephrol 15(6):1382\u20131391","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"103_CR86","doi-asserted-by":"crossref","first-page":"F418","DOI":"10.1152\/ajprenal.90319.2008","volume":"296","author":"B Vollenbr\u00f6ker","year":"2009","unstructured":"Vollenbr\u00f6ker B, George B, Wolfgart M, Saleem MA, Pavenst\u00e4dt H, Weide T (2009) mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes. Am J Physiol Renal Physiol 296(2):F418\u2013F426","journal-title":"Am J Physiol Renal Physiol"},{"issue":"11","key":"103_CR87","doi-asserted-by":"crossref","first-page":"e80340","DOI":"10.1371\/journal.pone.0080340","volume":"8","author":"S M\u00fcller-Krebs","year":"2013","unstructured":"M\u00fcller-Krebs S, Weber L, Tsobaneli J et al (2013) Cellular effects of everolimus and sirolimus on podocytes. PLoS One 8(11):e80340","journal-title":"PLoS One"},{"issue":"9","key":"103_CR88","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1097\/TP.0b013e318211d342","volume":"91","author":"G Stallone","year":"2011","unstructured":"Stallone G, Infante B, Pontrelli P et al (2011) Sirolimus and proteinuria in renal transplant patients: evidence for a dose-dependent effect on slit diaphragm-associated proteins. Transplantation 91(9):997\u20131004","journal-title":"Transplantation"},{"key":"103_CR89","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/ctr.12144","volume":"27","author":"MC Baas","year":"2013","unstructured":"Baas MC, Kers J, Florquin S et al (2013) Cyclosporine versus everolimus: effects on the glomerulus. Clin Transplant 27:535\u2013540","journal-title":"Clin Transplant"},{"key":"103_CR90","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1097\/01.ASN.0000057542.86377.5A","volume":"14","author":"KD Smith","year":"2003","unstructured":"Smith KD, Wrenshall LE, Nicosia RF et al (2003) Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use. J Am Soc Nephrol 14:1037\u20131045","journal-title":"J Am Soc Nephrol"},{"key":"103_CR91","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/ndt\/gfh079","volume":"19","author":"FC Fervenza","year":"2004","unstructured":"Fervenza FC, Fitzpatrick PM, Mertz J, For the Mayo Nephrology Collaborative Group et al (2004) Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. Nephrol Dial Transplant 19:1288\u20131292","journal-title":"Nephrol Dial Transplant"},{"key":"103_CR92","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1161\/01.RES.76.3.412","volume":"76","author":"SO Marx","year":"1995","unstructured":"Marx SO, Jayaraman T, Go LO, Marks AR (1995) Rapamycin\u2013FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 76:412\u2013417","journal-title":"Circ Res"},{"issue":"1","key":"103_CR93","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/1479-5876-11-292","volume":"11","author":"V Masola","year":"2013","unstructured":"Masola V, Zaza G, Granata S, Gambaro G, Onisto M, Lupo A (2013) Everolimus-induced epithelial to mesenchymal transition in immortalized human renal proximal tubular epithelial cells: key role of heparanase. J Transl Med 11(1):292","journal-title":"J Transl Med"},{"issue":"3","key":"103_CR94","doi-asserted-by":"crossref","first-page":"e32516","DOI":"10.1371\/journal.pone.0032516","volume":"7","author":"M Kurdi\u00e1n","year":"2012","unstructured":"Kurdi\u00e1n M, Herrero-Fresneda I, Lloberas N et al (2012) Delayed mTOR inhibition with low dose of everolimus reduces TGF\u03b2 expression, attenuates proteinuria and renal damage in the renal mass reduction model. PLoS One 7(3):e32516","journal-title":"PLoS One"},{"issue":"5","key":"103_CR95","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/ki.2010.457","volume":"79","author":"EK Geissler","year":"2011","unstructured":"Geissler EK, Schlitt HJ (2011) mTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression. Kidney Int 79(5):502\u2013511","journal-title":"Kidney Int"},{"issue":"1","key":"103_CR96","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/01.tp.0000296831.91303.9a","volume":"85","author":"P Pontrelli","year":"2008","unstructured":"Pontrelli P, Rossini M, Infante B et al (2008) Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy. Transplantation 85(1):125\u2013134","journal-title":"Transplantation"},{"issue":"4","key":"103_CR97","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/1535-7163.MCT-08-0668","volume":"8","author":"M Breuleux","year":"2009","unstructured":"Breuleux M, Klopfenstein M, Stephan C et al (2009) Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3 K\/mTOR inhibition. Mol Cancer Ther 8(4):742\u2013753","journal-title":"Mol Cancer Ther"},{"issue":"13","key":"103_CR98","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/sj.onc.1209990","volume":"26","author":"X Wan","year":"2007","unstructured":"Wan X, Harkavy B, Shen N, Grohar P, Helman LJ (2007) Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26(13):1932\u20131940","journal-title":"Oncogene"},{"issue":"4","key":"103_CR99","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.devcel.2007.03.020","volume":"12","author":"PT Bhaskar","year":"2007","unstructured":"Bhaskar PT, Hay N (2007) The two TORCs and Akt. Dev Cell 12(4):487\u2013502","journal-title":"Dev Cell"},{"issue":"21","key":"103_CR100","doi-asserted-by":"crossref","first-page":"5856","DOI":"10.1158\/1078-0432.CCR-12-0662","volume":"18","author":"BM Slomovitz","year":"2012","unstructured":"Slomovitz BM, Coleman RL (2012) The PI3 K\/AKT\/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res 18(21):5856\u20135864","journal-title":"Clin Cancer Res"},{"issue":"10","key":"103_CR101","first-page":"2658","volume":"63","author":"C Gilles","year":"2003","unstructured":"Gilles C, Polette M, Mestdagt M et al (2003) Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer Res 63(10):2658\u20132664","journal-title":"Cancer Res"},{"issue":"8","key":"103_CR102","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.bbamcr.2011.05.004","volume":"1813","author":"V Masola","year":"2011","unstructured":"Masola V, Gambaro G, Tibaldi E, Onisto M, Abaterusso C, Lupo A (2011) Regulation of heparanase by albumin and advanced glycation end products in proximal tubular cells. Biochim Biophys Acta 1813(8):1475\u20131482","journal-title":"Biochim Biophys Acta"},{"key":"103_CR103","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/1479-5876-10-213","volume":"10","author":"V Masola","year":"2012","unstructured":"Masola V, Onisto M, Zaza G, Lupo A, Gambaro G (2012) A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition. J Transl Med 10:213","journal-title":"J Transl Med"},{"key":"103_CR104","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/1471-2407-9-304","volume":"9","author":"V Masola","year":"2009","unstructured":"Masola V, Maran C, Tassone E, Zin A, Rosolen A, Onisto M (2009) Heparanase activity in alveolar and embryonal rhabdomyosarcoma: implications for tumor invasion. BMC Cancer 9:304","journal-title":"BMC Cancer"},{"issue":"3","key":"103_CR105","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1172\/JCI13662","volume":"108","author":"I Vlodavsky","year":"2001","unstructured":"Vlodavsky I, Friedmann Y (2001) Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 108(3):341\u2013347","journal-title":"J Clin Invest"},{"key":"103_CR106","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1007\/s00018-008-7584-6","volume":"65","author":"NJ Nasser","year":"2008","unstructured":"Nasser NJ (2008) Heparanase involvement in physiology and disease. Cell Mol Life Sci 65:1706\u20131715","journal-title":"Cell Mol Life Sci"},{"key":"103_CR107","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1582-4934.2007.00039.x","volume":"11","author":"V Vreys","year":"2007","unstructured":"Vreys V, David G (2007) Mammalian heparanase: what is the message? J Cell Mol Med 11:427\u2013452","journal-title":"J Cell Mol Med"},{"key":"103_CR108","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00005-009-0061-6","volume":"58","author":"M Szymczak","year":"2010","unstructured":"Szymczak M, Kuzniar J, Klinger M (2010) The role of heparanase in diseases of the glomeruli. Arch Immunol Ther Exp (Warsz) 58:45\u201356","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"9","key":"103_CR109","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1177\/1535370213498976","volume":"238","author":"X Xu","year":"2013","unstructured":"Xu X, Wan X, Geng J, Li F, Yang T, Dai H (2013) Rapamycin regulates connective tissue growth factor expression of lung epithelial cells via phosphoinositide 3-kinase. Exp Biol Med (Maywood) 238(9):1082\u20131094","journal-title":"Exp Biol Med (Maywood)"},{"issue":"1","key":"103_CR110","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bcp.2009.07.015","volume":"79","author":"S Nakagawa","year":"2010","unstructured":"Nakagawa S, Masuda S, Nishihara K, Inui K (2010) mTOR inhibitor everolimus ameliorates progressive tubular dysfunction in chronic renal failure rats. Biochem Pharmacol 79(1):67\u201376","journal-title":"Biochem Pharmacol"},{"issue":"10","key":"103_CR111","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/j.1432-2277.2006.00361.x","volume":"19","author":"SL Lui","year":"2006","unstructured":"Lui SL, Chan KW, Tsang R, Yung S, Lai KN, Chan TM (2006) Effect of rapamycin on renal ischemia-reperfusion injury in mice. Transpl Int 19(10):834\u2013839","journal-title":"Transpl Int"},{"issue":"1","key":"103_CR112","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.transproceed.2009.11.013","volume":"42","author":"F Cicora","year":"2010","unstructured":"Cicora F, Lausada N, Vasquez DN et al (2010) Sirolimus in kidney transplant donors and clinical and histologic improvement in recipients: rat model. Transplant Proc 42(1):365\u2013370","journal-title":"Transplant Proc"},{"issue":"11","key":"103_CR113","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1097\/01.TP.0000095897.38634.30","volume":"76","author":"TF Fuller","year":"2003","unstructured":"Fuller TF, Freise CE, Serkova N, Niemann CU, Olson JL, Feng S (2003) Sirolimus delays recovery of rat kidney transplants after ischemia-reperfusion injury. Transplantation 76(11):1594\u20131599","journal-title":"Transplantation"},{"issue":"5","key":"103_CR114","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1046\/j.1523-1755.2000.00045.x","volume":"57","author":"LA Hebert","year":"2000","unstructured":"Hebert LA, Agarwal G, Sedmak DD, Mahan JD, Becker W, Nagaraja HN (2000) Proximal tubular epithelial hyperplasia in patients with chronic glomerular proteinuria. Kidney Int 57(5):1962\u20131967","journal-title":"Kidney Int"},{"key":"103_CR115","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/00007890-200109150-00008","volume":"72","author":"E Morelon","year":"2001","unstructured":"Morelon E, Stern M, Israel-Biet D, Kreis H et al (2001) Characteristics of sirolimus associated interstitial pneumonitis in renal transplant patient. Transplantation 72:787\u2013790","journal-title":"Transplantation"},{"issue":"8","key":"103_CR116","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1016\/j.transproceed.2010.07.066","volume":"42","author":"P Errasti","year":"2010","unstructured":"Errasti P, Izquierdo D, Mart\u00edn P et al (2010) Pneumonitis associated with mammalian target of rapamycin inhibitors in renal transplant recipients: a single-center experience. Transplant Proc 42(8):3053\u20133054","journal-title":"Transplant Proc"},{"issue":"6","key":"103_CR117","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/j.transproceed.2009.06.003","volume":"41","author":"A Rodr\u00edguez-Moreno","year":"2009","unstructured":"Rodr\u00edguez-Moreno A, Ridao N, Garc\u00eda-Ledesma P et al (2009) Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center. Transplant Proc 41(6):2163\u20132165","journal-title":"Transplant Proc"},{"issue":"10","key":"103_CR118","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1093\/ndt\/gfn401","volume":"23","author":"S Alexandru","year":"2008","unstructured":"Alexandru S, Ortiz A, Baldovi S et al (2008) Severe everolimus-associated pneumonitis in a renal transplant recipient. Nephrol Dial Transplant 23(10):3353\u20133355","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"103_CR119","doi-asserted-by":"crossref","first-page":"505","DOI":"10.7326\/0003-4819-144-7-200604040-00009","volume":"144","author":"L Champion","year":"2006","unstructured":"Champion L, Stern M, Isra\u00ebl-Biet D et al (2006) Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann Intern Med 144(7):505\u2013509","journal-title":"Ann Intern Med"},{"issue":"8","key":"103_CR120","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1097\/01.TP.0000118413.92211.B6","volume":"77","author":"PT Pham","year":"2004","unstructured":"Pham PT, Pham PC, Danovitch GM et al (2004) Sirolimus-associated pulmonary toxicity. Transplantation 77(8):1215\u20131220","journal-title":"Transplantation"},{"issue":"2","key":"103_CR121","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1378\/chest.09-0780","volume":"137","author":"B Vandewiele","year":"2010","unstructured":"Vandewiele B, Vandecasteele SJ, Vanwalleghem L, De Vriese AS (2010) Diffuse alveolar hemorrhage induced by everolimus. Chest 137(2):456\u2013459","journal-title":"Chest"},{"issue":"4","key":"103_CR122","doi-asserted-by":"crossref","first-page":"541","DOI":"10.4065\/79.4.541","volume":"79","author":"NE Vlahakis","year":"2004","unstructured":"Vlahakis NE, Rickman OB, Morgenthaler T (2004) Sirolimus-associated diffuse alveolar hemorrhage. Mayo Clin Proc 79(4):541\u2013545","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"103_CR123","first-page":"297","volume":"33","author":"G Molas-Ferrer","year":"2013","unstructured":"Molas-Ferrer G, Soy-Muner D, Anglada-Mart\u00ednez H et al (2013) Interstitial pneumonitis as an adverse reaction to mTOR inhibitors. Nefrologia 33(3):297\u2013300","journal-title":"Nefrologia"},{"key":"103_CR124","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1746-1596-7-25","volume":"7","author":"S Kirby","year":"2012","unstructured":"Kirby S, Satoskar A, Brodsky S et al (2012) Histological spectrum of pulmonary manifestations in kidney transplant recipients on sirolimus inclusive immunosuppressive regimens. Diagn Pathol 7:25","journal-title":"Diagn Pathol"},{"issue":"12","key":"103_CR125","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1111\/j.1600-6143.2004.00612.x","volume":"4","author":"JJ Augustine","year":"2004","unstructured":"Augustine JJ, Knauss TC, Schulak JA et al (2004) Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am J Transplant 4(12):2001\u20132006","journal-title":"Am J Transplant"},{"issue":"2","key":"103_CR126","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2165\/11585040-000000000-00000","volume":"34","author":"S Sofroniadou","year":"2011","unstructured":"Sofroniadou S, Goldsmith D (2011) Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects. Drug Saf 34(2):97\u2013115","journal-title":"Drug Saf"},{"key":"103_CR127","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1097\/00007890-199810270-00013","volume":"66","author":"BD Kahan","year":"1998","unstructured":"Kahan BD, Podbielski J, Napoli KL et al (1998) Immunosuppressive effects and safety of a sirolimus\/cyclosporine combination regimen for renal transplantation. Transplantation 66:1040\u20131046","journal-title":"Transplantation"},{"key":"103_CR128","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1097\/01.tp.0000179106.07382.6a","volume":"80","author":"O Thaunat","year":"2005","unstructured":"Thaunat O, Beaumont C, Chatenoud L et al (2005) Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state. Transplantation 80:1212\u20131219","journal-title":"Transplantation"},{"key":"103_CR129","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1097\/01.tp.0000235545.49391.1b","volume":"82","author":"A Maiorano","year":"2006","unstructured":"Maiorano A, Stallone G, Schena A et al (2006) Sirolimus interferes with iron homeostasis in renal transplant recipients. Transplantation 82:908\u2013912","journal-title":"Transplantation"},{"issue":"7","key":"103_CR130","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1016\/j.transproceed.2007.06.032","volume":"39","author":"A S\u00e1nchez Fructuoso","year":"2007","unstructured":"S\u00e1nchez Fructuoso A, Calvo N, Moreno MA et al (2007) Study of anemia after late introduction of everolimus in the immunosuppressive treatment of renal transplant patients. Transplant Proc 39(7):2242\u20132244","journal-title":"Transplant Proc"},{"issue":"2","key":"103_CR131","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/ndt\/gfr318","volume":"27","author":"F Diekmann","year":"2012","unstructured":"Diekmann F, Rovira J, Diaz-Ricart M et al (2012) mTOR inhibition and erythropoiesis: microcytosis or anaemia? Nephrol Dial Transplant 27(2):537\u2013541","journal-title":"Nephrol Dial Transplant"},{"key":"103_CR132","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/ki.1996.28","volume":"49","author":"MG Murgia","year":"1996","unstructured":"Murgia MG, Jordan S, Kahan BD (1996) The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 49:209\u2013216","journal-title":"Kidney Int"},{"issue":"10","key":"103_CR133","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1097\/00007890-200005270-00019","volume":"69","author":"JC Hong","year":"2007","unstructured":"Hong JC, Kahan BD (2007) Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management. Transplantation 69(10):2085\u20132090","journal-title":"Transplantation"},{"issue":"6","key":"103_CR134","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/00007890-200203270-00016","volume":"73","author":"JM Kovarik","year":"2002","unstructured":"Kovarik JM, Kaplan B, Tedesco Silva H et al (2002) Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation 73(6):920\u2013925","journal-title":"Transplantation"},{"key":"103_CR135","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1093\/ndt\/13.12.3153","volume":"13","author":"A Babinska","year":"1998","unstructured":"Babinska A, Markell MS, Salifu MO et al (1998) Enhancement of human platelet aggregation and secretion induced by rapamycin. Nephrol Dial Transplant 13:3153\u20133159","journal-title":"Nephrol Dial Transplant"},{"issue":"19","key":"103_CR136","doi-asserted-by":"crossref","first-page":"7512","DOI":"10.1073\/pnas.87.19.7512","volume":"87","author":"SR Paul","year":"1990","unstructured":"Paul SR, Bennett F, Calvetti JA et al (1990) Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proc Natl Acad Sci USA 87(19):7512\u20137516","journal-title":"Proc Natl Acad Sci USA"},{"key":"103_CR137","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1182\/blood.V84.5.1543.1543","volume":"84","author":"VF Quesniaux","year":"1994","unstructured":"Quesniaux VF, Wehrli S, Steiner C et al (1994) The immuno-suppressant rapamycin blocks in vitro responses to hematopoietic cytokines and inhibits recovering but not steady-state hematopoiesis in vivo. Blood 84:1543\u20131552","journal-title":"Blood"},{"issue":"2","key":"103_CR138","first-page":"51","volume":"54","author":"BA Kiberd","year":"2002","unstructured":"Kiberd BA (2002) Cardiovascular risk reduction in renal transplantation. Strategies for success. Minerva Urol Nefrol 54(2):51\u201363","journal-title":"Minerva Urol Nefrol"},{"key":"103_CR139","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1194\/jlr.M100392-JLR200","volume":"43","author":"JD Morrisett","year":"2002","unstructured":"Morrisett JD, Abdel-Fattah G, Hoogeveen et al (2002) Effects of Sirolimus on plasma lipid, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 43:1170\u20131180","journal-title":"J Lipid Res"},{"key":"103_CR140","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1016\/j.transproceed.2004.10.086","volume":"36","author":"Q-Y Liu","year":"2004","unstructured":"Liu Q-Y, Nambi P (2004) Sirolimus upregulates aP2 expression in human monocytes and macrophages. Transplant Proc 36:3229\u20133231","journal-title":"Transplant Proc"},{"issue":"6","key":"103_CR141","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/89076","volume":"7","author":"L Makowski","year":"2001","unstructured":"Makowski L, Boord JB, Maeda K et al (2001) Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med 7(6):699\u2013705","journal-title":"Nat Med"},{"issue":"7","key":"103_CR142","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/j.1600-6143.2008.02272.x","volume":"8","author":"BL Kasiske","year":"2008","unstructured":"Kasiske BL, de Mattos A, Flechner SM et al (2008) Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant 8(7):1384\u20131392","journal-title":"Am J Transplant"},{"key":"103_CR143","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.transproceed.2006.03.072","volume":"38","author":"J Romagnoli","year":"2006","unstructured":"Romagnoli J, Citterio F, Nanni G et al (2006) Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine. Transplant Proc 38:1034\u20131036","journal-title":"Transplant Proc"},{"key":"103_CR144","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1681\/ASN.2005050487","volume":"16","author":"A Teutonico","year":"2005","unstructured":"Teutonico A, Schena PF, Di Paolo S (2005) Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 16:3128\u20133135","journal-title":"J Am Soc Nephrol"},{"key":"103_CR145","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/01.TP.0000176482.63122.03","volume":"80","author":"E Sulanc","year":"2005","unstructured":"Sulanc E, Lane JT, Puumala SE et al (2005) New-onset diabetes after kidney transplantation: an application of 2003 International Guidelines. Transplantation 80:945\u2013952","journal-title":"Transplantation"},{"key":"103_CR146","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1023\/A:1007159422667","volume":"211","author":"NA Syed","year":"2000","unstructured":"Syed NA, Khandelwal RL (2000) Reciprocal regulation of glycogen phosphorylase and glycogen synthase by insulin involving phosphatidylinositol-3 kinase and protein phosphatase-1 in HepG2 cells. Mol Cell Biochem 211:123\u2013136","journal-title":"Mol Cell Biochem"},{"key":"103_CR147","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1210\/edrv.23.2.0461","volume":"23","author":"GF Lewis","year":"2002","unstructured":"Lewis GF, Carpentier A, Adeli K, Giacca A (2002) Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 23:201\u2013229","journal-title":"Endocr Rev"},{"key":"103_CR148","doi-asserted-by":"crossref","first-page":"E630","DOI":"10.1152\/ajpendo.2000.279.3.E630","volume":"279","author":"SD Mittelman","year":"2000","unstructured":"Mittelman SD, Bergman RN (2000) Inhibition of lipolysis causes suppression of endogenous glucose production independent of changes in insulin. Am J Physiol Endocrinol Metab 279:E630\u2013E637","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"103_CR149","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1007\/s00125-006-0374-5","volume":"49","author":"CT Bussiere","year":"2006","unstructured":"Bussiere CT, Lakey JR, Shapiro AM, Korbutt GS (2006) The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells. Diabetologia 49:2341\u20132349","journal-title":"Diabetologia"},{"issue":"9","key":"103_CR150","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1034\/j.1600-6143.2003.00185.x","volume":"3","author":"J Valente","year":"2003","unstructured":"Valente J, Hricik D, Weigel K et al (2003) Comparison of sirolimus versus mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation. Am J Transplant 3(9):1128\u20131134","journal-title":"Am J Transplant"},{"issue":"10","key":"103_CR151","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1097\/01.TP.0000123082.31092.53","volume":"77","author":"PG Dean","year":"2004","unstructured":"Dean PG, Lund WJ, Larson TS et al (2004) Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 77(10):1555\u20131561","journal-title":"Transplantation"},{"issue":"2","key":"103_CR152","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s11255-009-9601-6","volume":"42","author":"A Srivastava","year":"2010","unstructured":"Srivastava A, Muruganandham K, Vinodh PB et al (2010) Post-renal transplant surgical complications with newer immunosuppressive drugs: mycophenolate mofetil vs. m-TOR inhibitors. Int Urol Nephrol 42(2):279\u2013284","journal-title":"Int Urol Nephrol"},{"issue":"1\u20132","key":"103_CR153","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0041-1345(96)00325-9","volume":"29","author":"R Nair","year":"1997","unstructured":"Nair R, Huang X, Shorthouse R et al (1997) Antiproliferative effect of rapamycin on growth factor-stimulated human adult lung fibroblasts in vitro may explain its superior efficacy for prevention and treatment of allograft obliterative airway disease in vivo. Transplant Proc 29(1\u20132):614\u2013615","journal-title":"Transplant Proc"},{"issue":"3","key":"103_CR154","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1365-2249.2009.04065.x","volume":"159","author":"G Zaza","year":"2010","unstructured":"Zaza G, Granata S, Sallustio F, Grandaliano G, Schena FP (2010) Pharmacogenomics: a new paradigm to personalize treatments in nephrology patients. Clin Exp Immunol 159(3):268\u2013280","journal-title":"Clin Exp Immunol"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-014-0103-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40620-014-0103-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-014-0103-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:57:48Z","timestamp":1777564668000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/27\/5\/495\/8372188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,8]]},"references-count":154,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["103"],"URL":"https:\/\/doi.org\/10.1007\/s40620-014-0103-y","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,8]]}}}